Home

News

Michael Conway accepts tenancy at 8 New Square27 June 2017Chambers is delighted to announce that Michael Conway has accepted an offer of tenancy which he will take up on the completion of pupillage at the end of September. Michael holds a DPhil from Wolfson College, Oxford and a First Class degree in Biochemistry from Trinity College, Oxford. During pupillage Michael has been involved in […]
Astex Therapeutics Ltd -v- Astrazeneca Ab [2017] EWHC 1442 (Ch)21 June 2017James Mellor QC and James Whyte appeared for the Defendant, AstraZeneca, in a case concerning payments under a collaboration agreement between AstraZeneca and the Claimant, Astex. The terms of the agreement provided that Astex were entitled to milestone payments in certain circumstances, and to royalties from sales of any products containing a “collaboration compound”. Astex […]
Astex Therapeutics Ltd -v- Astrazeneca Ab [2017] EWHC 1442 (Ch)21 June 2017James Mellor QC and James Whyte appeared for the Defendant, AstraZeneca, in a case concerning payments under a collaboration agreement between AstraZeneca and the Claimant, Astex. The terms of the agreement provided that Astex were entitled to milestone payments in certain circumstances, and to royalties from sales of any products containing a “collaboration compound”. Astex […]
Federation International De L’automobile v Gator Sports Ltd16 June 2017Jonathan Hill successfully represented the Claimant (FIA), the sporting body in charge of motor sport, in a claim in the Chancery Division for trade mark infringement and passing off in relation to articles of clothing sold by the Defendant companies after expiry of an official merchandise license relating to the World Rally Championship (WRC). Shortly […]
Unwired Planet International Ltd v Huawei Technologies Co Ltd [2017] EWHC 1304 (Pat)8 June 2017Adrian Speck QC, Isabel Jamal and Thomas Jones appeared for the claimant, Unwired Planet, and Andrew Lykiardopoulos QC appeared for the defendant, Huawei, in this hearing which considered remedies, in particular the appropriate form of a “FRAND injunction”, following the Court’s earlier ruling ([2017] EWHC 711 (Pat)) on the terms of a FRAND licence. Among […]
Unwired Planet International Ltd (Claimant) -v-(1) Huawei Technologies Co Ltd (2) Huawei Technologies (Uk) Co Ltd (Defendants) & Unwired Planet Llc (Tenth Party)7 June 2017Adrian Speck QC, Isabel Jamal and Thomas Jones appeared for the claimant, Unwired Planet, and Andrew Lykiardopoulos QC appeared for the defendant, Huawei, in this hearing which considered remedies, in particular the appropriate form of a “FRAND injunction”, following the Court’s earlier ruling ([2017] EWHC 711 (Pat)) on the terms of a FRAND licence. Among […]
Wellbeing at the Bar22 May 2017Charlotte May QC was part of a panel of experts speaking at the Wellbeing Evening hosted by the Bar Representation Committee at Lincoln’s Inn on 8 May 2017. The panel discussion included advice about how to raise awareness of wellbeing issues and to use wellbeing resources to provide support in the workplace. The closing address […]
Synthon v Teva [2017] EWCA Civ 14822 May 2017Andrew Lykiardopoulos QC represented the Appellant, Synthon, in its appeal concerning Teva’s patent for glatiramer acetate (marketed as “Copaxone”). The Patent related to a method of making glatiramer acetate with limited levels bromine and free metal impurities. Synthon had challenged the validity of the patent on grounds of lack of novelty, obviousness and insufficiency. At […]
Varian Medical Systems International AG v Elekta [2017] EWHC 712 (Pat)18 May 2017James Abrahams QC and James Whyte successfully represented the Defendants (Elekta) in Varian’s claim for infringement of its patent for a combined MRI and radiotherapy device. Elekta denied that its combined MRI and radiotherapy machine infringed the Patent, and further claimed that the Patent was invalid for insufficiency, obviousness and added matter. The judge held […]
Teva UK Ltd v Merck Sharp & Dohme Corp [2017] EWHC 539 (Pat)17 May 2017Charlotte May QC and Lindsay Lane represented the first claimant (“Teva”) in its successful challenge of the defendant’s (“Merck”) supplementary protection certificate (SPC) for an anti-viral drug marketed as Atripla.   The SPC covered a combination of the active ingredient efavirenz together with emtricitabine and tenofovir. The Court agreed with Teva’s case that the SPC […]